International Patent: HETEROCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT AND USE THEREOF

GENEVA, July 31 -- THE UNITED BIO-TECHNOLOGY (HENGQIN) CO., LTD. filed a patent application (CN2026/073894) for “HETEROCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT AND USE THEREOF”. With publication no. WO/2026/158353, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C07D 471/04

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....